Evidence map›Paper›PMID 37751164›Full record

SynthesisThe British journal of radiology2023

Radiotherapy of orbital metastases: a systematic review of management and treatment outcomes on behalf of palliative care study group of Italian association of radiotherapy and clinical oncology (AIRO).

Donato Pezzulla, Rossella Di Franco, Alice Zamagni, Francesco Pastore, Silvia Longo, Luca Dominici, Sara Lillo, Antonella Ciabattoni, Fabio Arcidiacono, Francesco Deodato and 4 more

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in The British journal of radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Progressive Unilateral Proptosis and [World journal of nuclear medicine · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Donato PezzullaRadiation Oncology Unit, Responsible Research Hospital, Largo A. Gemelli 1, Campobasso, Italy.ORCID 0000-0001-6676-1169
Rossella Di FrancoDepartment of Radiation Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
Alice ZamagniRadiation Oncology, Department of Experimental Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-Bologna University, Bologna, Italy.
Francesco PastoreDipartimento di Diagnostica Per Immagini, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC di Radioterapia Oncologica, Radioterapia Oncologica ed Ematologia, Rome, Italy.
Silvia LongoDipartimento di Diagnostica Per Immagini, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC di Radioterapia Oncologica, Radioterapia Oncologica ed Ematologia, Rome, Italy.
Luca DominiciDepartment of Radiotherapy, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy.
Sara LilloRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.
Antonella CiabattoniUOC Radioterapia, Ospedale San Filippo Neri, ASL Roma 1, Rome, Italy.
Fabio ArcidiaconoRadiotherapy Oncology Centre, "S. Maria" Hospital, Terni, Italy.
Francesco DeodatoRadiation Oncology Unit, Responsible Research Hospital, Largo A. Gemelli 1, Campobasso, Italy.
Paolo MutoDepartment of Radiation Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
Alessio Giuseppe MorgantiRadiation Oncology, Department of Experimental Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-Bologna University, Bologna, Italy.
Francesco CelliniDipartimento di Diagnostica Per Immagini, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC di Radioterapia Oncologica, Radioterapia Oncologica ed Ematologia, Rome, Italy.
Ernesto MaranzanoUniversity of Perugia-Faculty of Medicine and Surgery Radiotherapy Oncology Centre-"S. Maria" Hospital, Terni, Italy.
Agostino Gemelli University Polyclinic · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITASL Roma · ITAzienda USL di Bologna · ITHumanitas University · ITSanta Maria Nuova Hospital · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Bologna · ITUniversity of Messina · ITUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe search the current literature on data regarding the role of RT in OM treatment, focusing on the improvement of symptoms and patient quality of life.

methodsThis systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations.

resultsFrom 340 citations, 60 papers were finally selected: 45 case reports and 15 case series. The case reports accounted for 47 patients. In 37/39 cases (95%), EBRT was done. Patients were mainly treated with 3DCRT, IMRT, and with SBRT. The most used RT regimens were 30 Gy in 10 fractions (23%) and 20-25 Gy in 5 fx (13%). No sever toxicity was reported. A median LC of 11 months (range 1-54 months) and a median OS of 12 months (range 1-54 months) were registered. Among the case series, a total of 457 patients were examined, 227 of whom underwent RT. The main used techniques were 3DCRT, CK, GK, SBRT, and BRT. RT doses could vary from 30 Gy/10 fractions to 60 Gy/30 fractions, 50 Gy/5 fractions, or 16.5-21 Gy in single fraction. No toxicity above G2 was reported. ORR could vary between 75 and 100%. Only two study provided information on response duration: a mean LC time of 22.8 months and a mean time to local progression of 5 months (range: 3-7). Regarding OS, the data were heterogeneous, ranging between 1 and 54 months.

conclusionsRT for OM seems to be a safe and feasible option. More information on the RT ideal techniques and dose are still needed. ADVANCES IN KNOWLEDGE: This paper tried to sum up the few and fragmented data on the use of radiotherapy for orbital metastases: the possible option ranged from 3D- and 2D-CRT to SBRT, CK, and GK, with different possible fractionations (30Gy in 10 fractions, 60 Gy/30 fractions, 20-50 Gy/5 fractions, or 16.5-21 Gy in single fraction). Regardless of the chosen approach, almost all treated patients experienced a benefit after RT in terms of OM-related symptom intensity reduction and a good acute and late toxicity profile.

Indexed as

Palliative CareRadiotherapy, ConformalHumansMedical OncologyQuality of LifeTreatment Outcome

Identifiers

PMID37751164
PMCPMC10607395
OpenAlexW4387033862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.